TIME convened the first-ever TIME100 Health Leadership Forum to bring together individuals driving innovation and creating ...

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

We recently compiled a list of the 8 Most Undervalued Value Stocks To Buy According To Analysts. In this article, we are ...

Shawn Li, principal scientist at Merck & Co., known as MSD outside the Unites States and Canada, talked about the importance ...

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

(Reuters) -Advisers to the Centers for Disease Control and Prevention on Wednesday recommended expanding the use of vaccines ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...

Merck & Co. has acquired Modifi Biosciences, a developer of cancer therapies that was spun out of Yale University, in a deal potentially worth more than $1 billion.

Under the terms of the agreement Merck, through a subsidiary, has acquired all outstanding shares of Modifi Biosciences for ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price ...

A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and ...

Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by ...